New Research Suggests Ozempic and Similar Drugs May Slow the Spread of Certain Cancers
Last updated: May 2026 | Source: 2026 ASCO Annual Meeting | Read time: ~10 min
GLP-1 receptor agonists have accumulated an expanding body of evidence across multiple therapeutic areas: glycemic control, weight loss, cardiovascular risk reduction, kidney disease, and sleep apnea, among others. The research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting adds a new and genuinely intriguing dimension to that picture — suggesting that GLP-1 drugs may be associated with reduced metastatic progression in several obesity-related cancers.
The findings deserve careful, precise characterization. This is observational research, not a randomized controlled trial. It identifies associations, not proven causation. It does not suggest that GLP-1 drugs treat or cure cancer, and it does not change the current standard of care for any cancer type. What it does do is generate a scientifically credible hypothesis — grounded in real-world patient data from more than 12,000 cancer patients — that GLP-1 signaling may influence tumor biology in ways that warrant rigorous prospective investigation.
This research also exists within a broader and more complex context. GLP-1 drugs have simultaneously attracted significant attention for adverse effects including gastroparesis, bowel obstruction, NAION vision loss, and pancreatitis. The same class of medications being studied for potential anti-cancer properties is also the subject of thousands of personal injury lawsuits in MDL 3094. Holding both realities simultaneously — potential benefit in one domain, documented harm in another — is essential for an accurate understanding of the GLP-1 class. Our benefits vs. risks page covers that broader framework in detail.
Why Researchers Are Studying GLP-1 Drugs and Cancer
The scientific rationale for studying GLP-1 drugs in the context of cancer is not arbitrary. It flows directly from the known biological connections between obesity, metabolic dysfunction, inflammation, and cancer risk. Excess adiposity is an established risk factor for at least thirteen cancer types, including breast, colorectal, liver, pancreatic, kidney, and endometrial cancers. The biological mechanisms linking obesity to cancer include chronic low-grade inflammation, elevated levels of insulin and insulin-like growth factor, altered sex hormone metabolism, and immune dysregulation — all of which can create conditions that favor tumor development and progression.
Because GLP-1 drugs address several of these pathways simultaneously — reducing body weight, improving insulin sensitivity, dampening systemic inflammation, and altering metabolic signaling — they are plausible candidates for influencing the biological environment in which obesity-related cancers develop and spread. The 2026 ASCO research represents the most substantial real-world data analysis to date asking whether that plausible hypothesis translates into a measurable clinical signal. For broader context on how these medications work at a mechanistic level, see our GLP-1 drugs — how they work page.
At the same time, it is worth noting that GLP-1 drugs have carried a Boxed Warning for thyroid C-cell tumors since Ozempic’s initial approval in 2017, and pancreatitis has been a recognized safety concern across the class for years. The cancer biology of GLP-1 medications is therefore not a newly opened question — it is one on which data has been accumulating in multiple directions simultaneously.
The 2026 ASCO Study: Design and Methodology
The research presented at the 2026 ASCO Annual Meeting used a real-world comparative effectiveness design. Rather than following patients through a prospective randomized trial — which would take years and has not yet been done for this question — researchers analyzed existing electronic health record data from a large patient database to compare outcomes between patients who received GLP-1 drugs and those who received a comparator medication.
The Study Population
Researchers analyzed records for more than 12,000 patients drawn from the TriNetX health database, a federated network of electronic health records from healthcare organizations across the United States. The study population was defined by two criteria: patients had a diagnosis of one of seven obesity-related cancers at stage I, II, or III — meaning localized or regionally advanced disease that had not yet progressed to stage IV — and they began either a GLP-1 receptor agonist or a DPP-4 inhibitor after their cancer diagnosis. The seven cancer types included were breast adenocarcinoma, prostate adenocarcinoma, non-small cell lung cancer, colorectal adenocarcinoma, hepatocellular carcinoma (liver cancer), renal cell carcinoma (kidney cancer), and pancreatic adenocarcinoma.
The Comparator: DPP-4 Inhibitors
The choice of comparator medication is methodologically important. DPP-4 inhibitors — sometimes called gliptins — are another class of diabetes drugs that work by slowing the breakdown of endogenous GLP-1, thereby indirectly amplifying GLP-1 activity but at much lower magnitude than GLP-1 receptor agonists, which directly activate the receptor with pharmacological potency. Using DPP-4 inhibitors as the comparison group rather than no medication or a completely different drug class helps control for the fact that both groups have diabetes, are being actively managed, and have some baseline level of incretin activity. The comparison is therefore between high-level direct GLP-1 receptor activation and lower-level indirect GLP-1 enhancement — a contrast that isolates the question of whether the magnitude of GLP-1 receptor engagement matters for cancer outcomes.
The GLP-1 drugs represented in the study included semaglutide, tirzepatide, dulaglutide, liraglutide, and lixisenatide. This diversity across multiple agents and mechanisms is a methodological strength: if the signal were confined to a single drug, it might reflect a drug-specific property; when it appears across the class, it is more consistent with a class-level mechanism.
The Primary Outcome
The primary outcome measure was progression to stage IV metastatic disease — the point at which cancer has spread to distant organs and curative treatment options become substantially more limited. Comparing the rates at which patients in each group progressed to stage IV is a clinically meaningful endpoint because metastatic progression is directly correlated with survival outcomes, quality of life, and treatment burden.
Main Study Findings
The most striking results were concentrated in four of the seven cancer types studied. Across lung, breast, colorectal, and liver cancers, GLP-1 users showed substantially lower rates of metastatic progression compared to patients on DPP-4 inhibitors. The magnitude of the differences was notable given the observational study design.
| Cancer Type | GLP-1 Users — Metastatic Rate | DPP-4 Users — Metastatic Rate |
| Non-small cell lung cancer | 10% | 22% |
| Breast adenocarcinoma | 10% | 20% |
| Colorectal adenocarcinoma | 13% | 22% |
| Hepatocellular carcinoma (liver) | 19% | 28% |
Across these four cancer types, researchers calculated that GLP-1 users were approximately 38 to 50 percent less likely to progress to stage IV metastatic disease compared to patients taking DPP-4 inhibitors. These are substantial differences, and they were statistically significant — meaning they are unlikely to reflect random variation in the data.
The results for the remaining three cancer types — prostate, kidney, and pancreatic cancers — showed a trend in the same direction, with fewer metastatic cases in the GLP-1 group, but the differences did not reach statistical significance. This distinction matters: a non-significant finding does not mean GLP-1 drugs have no effect in these cancers — it means the current data cannot support a confident conclusion either way. Larger studies or longer follow-up periods may be needed to detect an effect if one exists.
GLP-1 Receptor Expression in Tumors and Survival
A separate and complementary analysis in the same research program examined data from The Cancer Genome Atlas — a large publicly available dataset containing genomic and clinical information from thousands of cancer patients — to ask a related but distinct question: in patients whose tumors express GLP-1 receptors at higher levels, are survival outcomes better?
The answer, across the dataset as a whole, was yes. High GLP-1 receptor expression in tumor tissue was associated with a 33 percent lower risk of death compared to low GLP-1 receptor expression. The association was most pronounced in breast cancer, where high receptor expression correlated with approximately a 45 percent lower mortality risk.
This finding is biologically significant for a specific reason. It suggests that the GLP-1 signaling pathway itself — not simply the indirect metabolic effects of GLP-1 drugs such as weight loss or improved insulin sensitivity — may have a direct influence on cancer cell behavior. If tumors that express more GLP-1 receptors have better outcomes, it implies that GLP-1 signaling in those tumor cells may be suppressing malignant activity. This would be consistent with the hypothesis that GLP-1 receptor agonist drugs, by directly stimulating those same receptors, could produce similar tumor-level effects in patients whose cancers express GLP-1 receptors.
The GLP-1 receptor expression analysis raises the possibility that the benefit of GLP-1 drugs in certain cancers may reflect a direct tumor-level effect — not merely the metabolic consequences of weight loss — but this hypothesis requires prospective validation in controlled studies before clinical conclusions can be drawn.
Proposed Biological Mechanisms
How might GLP-1 receptor activation influence cancer progression? Researchers have proposed several non-mutually exclusive mechanisms, each grounded in established cancer biology. None has yet been definitively validated in the context of GLP-1 drugs and human cancer, but together they constitute a plausible explanatory framework for the observed associations.
1. Reduction of Systemic Inflammation
Chronic low-grade inflammation is one of the most well-established drivers of cancer progression. Inflammatory cytokines create a tumor microenvironment that supports cancer cell survival, local invasion, and metastatic spread. GLP-1 drugs have demonstrated anti-inflammatory effects across multiple studies — reducing circulating inflammatory markers including CRP and IL-6 — and this systemic dampening of the inflammatory milieu may reduce the biological conditions that favor metastatic progression, particularly in obesity-associated cancers where inflammation is a prominent feature.
2. Immune System Modulation
The relationship between GLP-1 signaling and immune function is an active area of research. GLP-1 receptors are expressed on several immune cell types, including macrophages, dendritic cells, and T lymphocytes — cells that play central roles in anti-tumor immune surveillance. There is preliminary evidence that GLP-1 receptor activation can shift macrophage polarization toward an anti-inflammatory phenotype and may enhance T-cell activity. If confirmed in the cancer biology context, these effects could improve the immune system’s capacity to recognize and eliminate early metastatic deposits before they establish themselves in distant organs.
3. Metabolic Reprogramming of the Tumor Environment
Cancer cells are metabolically distinct from normal cells: they have elevated glucose uptake and rely disproportionately on glycolytic metabolism to fuel their rapid growth. GLP-1 drugs alter systemic glucose and insulin dynamics in ways that may reduce the nutrient availability that supports this metabolic profile. Reduced systemic insulin levels — a consequence of improved glycemic control — may also reduce signaling through the insulin/IGF-1 pathway, which is a recognized promoter of cancer cell proliferation and survival across multiple tumor types.
4. Direct GLP-1 Receptor Signaling in Tumor Cells
The Cancer Genome Atlas analysis described above provides the most direct evidence for this mechanism: some tumor cells express GLP-1 receptors, and higher expression is associated with better survival. If GLP-1 receptor activation in tumor cells produces effects that limit their proliferative or invasive capacity, GLP-1 receptor agonist drugs could theoretically exert direct anti-tumor effects in receptor-expressing cancers. The molecular consequences of GLP-1 receptor signaling in cancer cells — including its effects on cell cycle regulation, apoptosis, and migration — are subjects of active preclinical investigation.
Important Limitations: What This Study Does and Does Not Show
The scientific excitement generated by the ASCO findings is understandable, but the limitations of the study design are important constraints on the conclusions that can responsibly be drawn. Overstating what observational research can establish does a disservice to both patients and the scientific process.
Observational Design: Association, Not Causation
The study analyzed existing health records; it did not randomly assign patients to GLP-1 drugs or DPP-4 inhibitors. This means the two patient groups may have differed in ways that influenced their cancer outcomes independently of the medications they received. Patients prescribed GLP-1 drugs may have been heavier at baseline, may have received different cancer treatments, may have had better access to follow-up care, or may have differed in dozens of other clinical and socioeconomic factors that affect cancer prognosis. Propensity-score matching and other statistical adjustments can reduce but cannot eliminate this confounding risk. The study identifies an association — that GLP-1 use is correlated with lower metastatic progression rates — but it cannot establish that GLP-1 drugs caused that difference.
Active Comparator Bias
The comparison group — DPP-4 inhibitor users — is a reasonable methodological choice but introduces its own complications. DPP-4 inhibitors are not inert; they have their own metabolic and potentially oncological effects. The observed advantage for GLP-1 users may partly reflect relative harms or benefits of DPP-4 inhibitors rather than absolute benefits of GLP-1 drugs. Comparing GLP-1 users to cancer patients on no diabetes medication at all might produce different results.
Follow-Up Duration and Database Limitations
Real-world database analyses are constrained by the completeness and accuracy of the underlying health records. Staging information, treatment details, and outcome data may be inconsistently recorded across the healthcare systems contributing to the TriNetX database. The follow-up duration available in this dataset may also be insufficient to capture the full natural history of cancer progression in some of the slower-moving tumor types studied.
What This Research Does Not Mean
Several conclusions that might be tempting to draw from these findings are not supported by the current evidence:
- GLP-1 drugs do not treat cancer and should not be taken for that purpose
- Patients currently taking GLP-1 drugs for diabetes or weight loss should not modify their cancer treatment plans based on this research
- The findings do not apply to cancer types not studied, and even within the studied cancers, the effects may not be uniform across all patients
- The study was not designed to evaluate whether GLP-1 drugs affect cancer incidence — only whether they affect metastatic progression in patients already diagnosed
Safety Findings Within the Study
One secondary finding from the ASCO research is worth noting in the context of the broader GLP-1 safety discussion. Within this study population, rates of gastrointestinal adverse events — including stomach inflammation and pancreatitis — were not significantly higher in the GLP-1 group than in the DPP-4 inhibitor group. The researchers reported that adverse-event rates were generally similar between the two treatment groups.
This finding should be interpreted with caution. The study was not designed as a safety analysis, the follow-up period may have been insufficient to capture long-term gastrointestinal injury development, and the cancer patient population may not be representative of the broader GLP-1 user population. The documented association between GLP-1 drugs and serious gastrointestinal injuries — including gastroparesis, bowel obstruction, and ileus — is established across much larger adverse event datasets and the MDL 3094 litigation record. A single observational oncology study does not and cannot revise that evidence base. For a full accounting of the documented serious side effects associated with GLP-1 medications, see our severe adverse reactions page.
The Dual Nature of GLP-1 Cancer Research
The ASCO findings exist alongside, not in place of, other cancer-related research on GLP-1 drugs that points in different directions. Since Ozempic’s first approval in 2017, the drug has carried a Boxed Warning — the FDA’s highest-level safety alert — for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma, based on animal study data. Pancreatitis, which has been associated with GLP-1 use across multiple drug class members and label updates, is a recognized risk factor for pancreatic cancer. And the 2026 ASCO analysis itself found no statistically significant reduction in metastatic progression in pancreatic cancer patients on GLP-1 drugs.
This complexity is not a reason to dismiss the ASCO findings, but it is a reason to hold them in appropriate scientific context. GLP-1 drugs are a pharmacologically diverse class with effects across multiple biological systems. Their relationship to cancer biology is not going to be captured by a single dataset or a single direction of association. What the ASCO research contributes is a credible signal — in specific cancer types, using a rigorous real-world methodology — that merits the prospective clinical trial investigation the researchers have called for.
Future Research Directions
The ASCO findings have generated substantive interest precisely because the observed effect sizes are large enough to be clinically meaningful if confirmed in randomized trials. Researchers have identified several areas where deeper investigation is most urgently needed:
- Prospective randomized controlled trials comparing GLP-1 drugs to appropriate comparators in cancer patients, with pre-specified cancer progression endpoints
- Mechanistic studies examining the direct effects of GLP-1 receptor activation on cancer cell proliferation, invasion, and apoptosis in cell-line and animal models
- Biomarker research to identify which cancer patients — based on tumor GLP-1 receptor expression levels or other molecular features — are most likely to show a benefit
- Longitudinal studies with longer follow-up periods to determine whether the metastasis-reduction signal persists over time and whether it translates into improved overall survival
- Investigation of whether specific GLP-1 agents or dual agonists like tirzepatide produce different effects than single-receptor GLP-1 drugs
For ongoing coverage of GLP-1 research developments, clinical trial results, and next-generation drug pipeline updates, see our clinical studies and research page and our pipeline tracker.
Key Takeaways
For patients, clinicians, and researchers following the expanding GLP-1 evidence base, the following points summarize the current state of the cancer progression research:
- A real-world analysis presented at the 2026 ASCO Annual Meeting found that GLP-1 drug users were 38 to 50 percent less likely to progress to stage IV metastatic disease compared to DPP-4 inhibitor users in four cancer types: lung, breast, colorectal, and liver
- The study analyzed data from more than 12,000 cancer patients in the TriNetX database; all patients had stage I–III disease at the time of GLP-1 or DPP-4 inhibitor initiation
- A complementary Cancer Genome Atlas analysis found that high GLP-1 receptor expression in tumor tissue was associated with 33 percent lower overall mortality risk, with the strongest association in breast cancer
- Proposed mechanisms include anti-inflammatory effects, immune modulation, metabolic reprogramming of the tumor environment, and direct GLP-1 receptor signaling in tumor cells
- The study is observational and does not establish causation; randomized controlled trials are required before clinical conclusions can be responsibly drawn
- These findings do not alter the established safety profile of GLP-1 drugs, which includes documented associations with gastroparesis, bowel obstruction, pancreatitis, NAION vision loss, and thyroid tumor risk
- GLP-1 drugs should not be taken for the purpose of influencing cancer outcomes outside of a clinical trial setting
The ASCO research is a genuinely significant contribution to the scientific literature on GLP-1 drugs and cancer biology. It opens a credible new chapter in the investigation of what these medications do beyond their approved indications. But it does so without closing the chapters already written about their documented risks — and responsible interpretation requires keeping both in view simultaneously.